Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1675
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18500684 | MONOCLONAL ANTIBODIES AGAINST SARS-COV-2 AND VARIANTS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18400897 | TRANSKETOLASE EPITOPES, METHODS, AND DEVICES FOR IGG-BASED TUBERCULOSIS SERODIAGNOSIS | Non-Final OA | Wayne State University |
| 18281977 | ANTI- ENOLASE 1 (ENO1) ANTIBODY AND APPLICATIONS THEREOF | Non-Final OA | Academia Sinica |
| 18519225 | COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITOR | Non-Final OA | NIPPON KAYAKU KABUSHIKI KAISHA |
| 18546947 | ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 18553686 | SALMONELLA VACCINE | Non-Final OA | University of Maryland, College Park |
| 18397180 | VACCINATION AGAINST FUNGAL EPITOPES TO PREVENT INFLAMMATORY BOWEL DISEASES | Non-Final OA | THE UNIVERSITY OF UTAH |
| 18573574 | YEAST FOR THE TREATMENT OF INFLAMMATION | Non-Final OA | Milmed Unico AB |
| 18288640 | NOVEL LACTOBACILLUS FERMENTUM ATG-V5 STRAIN, OR COMPOSITION FOR ENHANCING IMMUNITY COMPRISING SAME | Non-Final OA | Ji Hee KANG |
| 18265405 | ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18268844 | CONSTRUCTS COMPRISING SINGLE DOMAIN VHH ANTIBODIES AGAINST SARS COV-2 | Non-Final OA | Lumen Bioscience, Inc. |
| 18248238 | METHOD FOR TREATING OX40 RELATED DISEASE | Final Rejection | Kyowa Kirin Co., Ltd. |
| 18002591 | CD-3 ANTIBODIES FOR THE TREATMENT OF CORONAVIRUS | Non-Final OA | Tiziana Life Sciences PLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy